HSP90B1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL383810	0.54	14/20
SCHEMBL872294	0.55	12/20
SCHEMBL380889	0.59	11/20
SCHEMBL488087	0.48	10/20
SCHEMBL873984	0.70	9/20
SCHEMBL487957	0.46	8/20
SCHEMBL1219018	0.79	7/20
SCHEMBL1052264	0.71	7/20
SCHEMBL1059521	0.71	7/20
SCHEMBL382495	0.67	7/20
SCHEMBL1059740	0.66	7/20
SCHEMBL1058173	0.64	7/20
SCHEMBL1219082	0.64	7/20
SCHEMBL1079346	0.60	7/20
SCHEMBL1059052	0.59	7/20
SCHEMBL1057826	0.59	7/20
SCHEMBL1059577	0.59	7/20
SCHEMBL383083	0.58	7/20
SCHEMBL1078262	0.57	7/20
SCHEMBL1083386	0.57	7/20

Clinical trials — most relevant to HSP90B1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease	PHASE2	COMPLETED
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer	PHASE2	COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy	PHASE2	COMPLETED
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)	PHASE1/PHASE2	COMPLETED
OGX-427 in Castration Resistant Prostate Cancer Patients	PHASE2	COMPLETED
Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer	PHASE1/PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer	PHASE2	COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas	PHASE1	COMPLETED
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma	PHASE1	COMPLETED
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma	PHASE1	COMPLETED
HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies	PHASE1	WITHDRAWN
Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
The Role of HSP90 in Peripheral Vascular Lesions of Diabetic Atherosclerosis	nan	COMPLETED
LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC	nan	COMPLETED
Exercise on Expression of Heat Shock Protein 70 in Arterial Risk	nan	COMPLETED
Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer	nan	UNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)	nan	RECRUITING
Perfusion-Induced Hyperthermia for Metastatic Carcinoma	nan	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases.	nan	NOT_YET_RECRUITING
BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer	nan	UNKNOWN
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a HSP90B1 binder may also engage these)

Protein	Name	Similarity
P41148	—	1.000	P41148 →
Q5R6F7	—	1.000	Q5R6F7 →
Q95M18	—	1.000	Q95M18 →
P08110	—	1.000	P08110 →
P08113	—	1.000	P08113 →
Q29092	—	1.000	Q29092 →
Q4R520	—	1.000	Q4R520 →
Q66HD0	—	1.000	Q66HD0 →
O18750	—	1.000	O18750 →
Q04619	—	1.000	Q04619 →
Q22235	—	1.000	Q22235 →
P11501	—	1.000	P11501 →
P46633	—	1.000	P46633 →
Q4R4P1	—	1.000	Q4R4P1 →
Q9GKX7	—	1.000	Q9GKX7 →
Q9NGD0	—	1.000	Q9NGD0 →
P35016	—	1.000	P35016 →
O02192	—	1.000	O02192 →
A5A6K9	—	1.000	A5A6K9 →
HSP90AA1	Heat shock protein HSP 90-alpha	0.999	landscape →
Q76LV2	—	0.999	Q76LV2 →
P07901	—	0.999	P07901 →
P15108	—	0.999	P15108 →
P30946	—	0.999	P30946 →
P34058	—	0.999	P34058 →
P46598	—	0.999	P46598 →
O57521	—	0.999	O57521 →
HSP90AB1	Heat shock protein HSP 90-beta	0.999	landscape →
Q6AZV1	—	0.998	Q6AZV1 →
O02705	—	0.998	O02705 →